Current and proposed molecular diagnostics in a genitourinary service line laboratory at a tertiary clinical institution.
The idea that detailed knowledge of molecular oncogenesis will drive diagnostic, prognostic, and therapeutic clinical decision making in an increasingly multidisciplinary practice of oncologic care has been anticipated for many years. With the recent rapid advancement in our understanding of the molecular underpinnings of genitourinary malignancies, this concept is now starting to take shape in the fields of prostate, kidney, bladder, testicular, and penile cancer. Such breakthroughs necessitate the development of robust clinical-grade assays that can be quickly made available for patients to facilitate diagnosis in challenging cases, risk-stratify patients for subsequent clinical management, select the appropriate targeted therapy from among increasingly diverse and numerous options, and enroll patients in advanced clinical trials. This rapid translation of basic and clinical cancer research requires a streamlined, multidisciplinary approach to clinical assay development, termed here the molecular diagnostics service line laboratory. In this review, we summarize the current state and explore the future of molecular diagnostics in genitourinary oncology to conceptualize a genitourinary service line laboratory at a tertiary clinical institution.
From the Departments of *Pathology, †Internal Medicine, ‡Comprehensive Cancer Center, University of Michigan Health System; and §Michigan Center for Translational Pathology, Ann Arbor, MI.
Aaron M
AM
Udager
Ajjai
A
Alva
Rohit
R
Mehra
D006801:Humans; D007150:Immunohistochemistry; D007755:Laboratories, Hospital; D057089:Pathology, Molecular; D014565:Urogenital Neoplasms / Q000175:diagnosis* / Q000378:metabolism / Q000473:pathology